AbbVie Inc. EBIT Margin

EBIT Margin of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBIT Margin growth rates and interactive chart. Earnings before interest and taxes margin is an indicator of a company's profitability. Calculated as earnings before interest and taxes (EBIT) divided by revenue. It is useful for comparison of companies with different debt levels and tax rates. And EBIT margin gives a clear picture about the underlying profitability of a company's core operations. EBIT is also referred to as operating earnings, operating profit, and profit before interest and taxes.


Highlights and Quick Summary

  • EBIT Margin for the quarter ending December 30, 2019 was 45.45% (a 47.28% increase compared to previous quarter)
  • Year-over-year quarterly EBIT Margin increased by 18.21%
  • Annual EBIT Margin for 2019 was 39.03% (a 100.26% increase from previous year)
  • Annual EBIT Margin for 2018 was 19.49% (a -42.39% decrease from previous year)
  • Annual EBIT Margin for 2017 was 33.83% (a -7.14% decrease from previous year)
  • Twelve month EBIT Margin ending December 30, 2019 was 39.03% (a 94.76% increase compared to previous quarter)
  • Twelve month trailing EBIT Margin increased by 96.33% year-over-year
Trailing EBIT Margin for the last four month:
30 Dec '19 29 Sep '19 29 Jun '19 30 Mar '19
39.03% 20.04% 21.85% 19.88%
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBIT Margin of AbbVie Inc.

Most recent EBIT Marginof ABBV including historical data for past 10 years.

Interactive Chart of EBIT Margin of AbbVie Inc.

AbbVie Inc. EBIT Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 45.45% 30.86% 41.19% 38.45% 39.03%
2018 -29.39% 38.36% 33.37% 36.59% 19.49%
2017 23.03% 38.51% 38.34% 36.82% 33.83%
2016 34.05% 36.71% 37.0% 38.23% 36.43%
2015 33.02% 31.71% 33.83% 33.47% 32.97%
2014 -7.61% 19.13% 30.76% 29.61% 17.09%
2013 30.03% 29.43% 30.97% 30.15% 30.14%
2012 34.98% 35.4% 31.65% 23.44% 31.65%
2011 -121.03% 100.0% 100.0% 21.16% 20.75%
2010 30.16%
2009 34.7%

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.